Primary Paraganglioma of the Prostate: A Systematic Review of the Literature for A Rare Entity
CONCLUSION: Due to atypical clinical manifestation and scarcity of prostatic paraganglioma, urologists should be aware of this extremely rare entity.PMID:38549519 | DOI:10.2174/0115748871293735240209052044 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 29, 2024 Category: Cancer & Oncology Authors: Ilias Giannakodimos Afroditi Ziogou Alexios Giannakodimos Evangelia Mitakidi Konstantinos Tzelepis Evangelos Fragkiadis Nikolaos Charalampakis Source Type: research
PMDA regulatory update on approval of new drugs and revisions of precautions; approval of talazoparib tosilate for prostate and breast cancer, and luspatercept for myelodysplastic syndrome in Japan
Int J Clin Oncol. 2024 Mar 29. doi: 10.1007/s10147-024-02510-6. Online ahead of print.NO ABSTRACTPMID:38551728 | DOI:10.1007/s10147-024-02510-6 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 29, 2024 Category: Cancer & Oncology Authors: Noriomi Matsumura Masaki Mandai Source Type: research
Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022
CONCLUSION: G-CSF may be beneficial as primary prophylaxis during CBZ administration for metastatic castration resistant prostate cancer, and we made a "weak recommendation to perform" with an annotation of the relevant regimen.PMID:38538963 | DOI:10.1007/s10147-024-02501-7 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 28, 2024 Category: Cancer & Oncology Authors: Shoji Kimura Keisuke Shigeta Shingo Tamura Keita Uchino Takahiro Kimura Yukinori Ozaki Hiroshi Nishio Kenji Tsuchihashi Eiki Ichihara Makoto Endo Shingo Yano Dai Maruyama Tetsuhiro Yoshinami Nobuyuki Susumu Munetaka Takekuma Takashi Motohashi Mamoru Ito E Source Type: research
Overexpression of Transmembrane Phosphatase with Tensin homology (TPTE) in prostate cancer is clinically significant, suggesting its potential as a valuable biomarker
CONCLUSION: Our findings indicate that increased TPTE expression is associated with progression of disease. The ability of anti-TPTE-p2 antibody to recognize and target the TPTE protein makes it a potential biomarker to assess and/or target the PCa.PMID:38546751 | PMC:PMC10978697 | DOI:10.1007/s00432-024-05694-6 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 28, 2024 Category: Cancer & Oncology Authors: Nahid Zainodini Maryam Abolhasani Monireh Mohsenzadegan Mohammad M Farajollahi Elham Rismani Source Type: research
Mediator kinase inhibition reverses castration resistance of advanced prostate cancer
J Clin Invest. 2024 Mar 28:e176709. doi: 10.1172/JCI176709. Online ahead of print.ABSTRACTMediator kinases CDK19 and CDK8, pleiotropic regulators of transcriptional reprogramming, are differentially regulated by androgen signaling but both kinases are upregulated in castration-resistant prostate cancer (CRPC). Genetic or pharmacological inhibition of CDK8 and CDK19 reverses the castration-resistant phenotype and restores the sensitivity of CRPC xenografts to androgen deprivation in vivo. Prolonged CDK8/19 inhibitor treatment combined with castration not only suppresses the growth of CRPC xenografts but also induces tumor r...
Source: Clinical Prostate Cancer - March 28, 2024 Category: Cancer & Oncology Authors: Jing Li Thomas A Hilimire Liu Yueying Lili Wang Jiaxin Liang Bal ázs Győrffy Vitali Sikirzhytski Hao Ji Li Zhang Chen Cheng Xiaokai Ding Kendall R Kerr Charles E Dowling Alexander A Chumanevich Zachary T Mack Gary P Schools Chang-Uk Lim Leigh Ellis Xiao Source Type: research
Decision regret of cancer patients after radiotherapy: results from a cross-sectional observational study at a large tertiary cancer center in Germany
CONCLUSIONS: The German version of the DRS could be used to assess decision regret in a diverse cohort of cancer patients undergoing radiotherapy. Decision regret was prevalent in a considerable proportion of patients. Further studies are necessary to validate these findings and obtain causal factors associated with decision regret after radiotherapy.PMID:38546873 | PMC:PMC10978708 | DOI:10.1007/s00432-024-05638-0 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 28, 2024 Category: Cancer & Oncology Authors: Alexander R ühle Leonie Wieland Andreas Hinz Anja Mehnert-Theuerkauf Nils H Nicolay Clemens Seidel Source Type: research
Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022
CONCLUSION: G-CSF may be beneficial as primary prophylaxis during CBZ administration for metastatic castration resistant prostate cancer, and we made a "weak recommendation to perform" with an annotation of the relevant regimen.PMID:38538963 | DOI:10.1007/s10147-024-02501-7 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 28, 2024 Category: Cancer & Oncology Authors: Shoji Kimura Keisuke Shigeta Shingo Tamura Keita Uchino Takahiro Kimura Yukinori Ozaki Hiroshi Nishio Kenji Tsuchihashi Eiki Ichihara Makoto Endo Shingo Yano Dai Maruyama Tetsuhiro Yoshinami Nobuyuki Susumu Munetaka Takekuma Takashi Motohashi Mamoru Ito E Source Type: research
Overexpression of Transmembrane Phosphatase with Tensin homology (TPTE) in prostate cancer is clinically significant, suggesting its potential as a valuable biomarker
CONCLUSION: Our findings indicate that increased TPTE expression is associated with progression of disease. The ability of anti-TPTE-p2 antibody to recognize and target the TPTE protein makes it a potential biomarker to assess and/or target the PCa.PMID:38546751 | DOI:10.1007/s00432-024-05694-6 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 28, 2024 Category: Cancer & Oncology Authors: Nahid Zainodini Maryam Abolhasani Monireh Mohsenzadegan Mohammad M Farajollahi Elham Rismani Source Type: research
Mediator kinase inhibition reverses castration resistance of advanced prostate cancer
J Clin Invest. 2024 Mar 28:e176709. doi: 10.1172/JCI176709. Online ahead of print.ABSTRACTMediator kinases CDK19 and CDK8, pleiotropic regulators of transcriptional reprogramming, are differentially regulated by androgen signaling but both kinases are upregulated in castration-resistant prostate cancer (CRPC). Genetic or pharmacological inhibition of CDK8 and CDK19 reverses the castration-resistant phenotype and restores the sensitivity of CRPC xenografts to androgen deprivation in vivo. Prolonged CDK8/19 inhibitor treatment combined with castration not only suppresses the growth of CRPC xenografts but also induces tumor r...
Source: Clinical Prostate Cancer - March 28, 2024 Category: Cancer & Oncology Authors: Jing Li Thomas A Hilimire Liu Yueying Lili Wang Jiaxin Liang Bal ázs Győrffy Vitali Sikirzhytski Hao Ji Li Zhang Chen Cheng Xiaokai Ding Kendall R Kerr Charles E Dowling Alexander A Chumanevich Zachary T Mack Gary P Schools Chang-Uk Lim Leigh Ellis Xiao Source Type: research
Decision regret of cancer patients after radiotherapy: results from a cross-sectional observational study at a large tertiary cancer center in Germany
CONCLUSIONS: The German version of the DRS could be used to assess decision regret in a diverse cohort of cancer patients undergoing radiotherapy. Decision regret was prevalent in a considerable proportion of patients. Further studies are necessary to validate these findings and obtain causal factors associated with decision regret after radiotherapy.PMID:38546873 | DOI:10.1007/s00432-024-05638-0 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 28, 2024 Category: Cancer & Oncology Authors: Alexander R ühle Leonie Wieland Andreas Hinz Anja Mehnert-Theuerkauf Nils H Nicolay Clemens Seidel Source Type: research
A phase I trial of enzalutamide plus selective glucocorticoid receptor modulator relacorilant in patients with metastatic castration resistant prostate cancer
CONCLUSIONS: This is the first prospective trial combining an AR antagonist and a non-steroidal selective GR modulator. The combination was safe and well tolerated with PSA response and prolonged disease control observed in a limited subset of patients. Further prospective trials are justified to evaluate efficacy and identify predictive biomarkers of response.PMID:38536082 | DOI:10.1158/1078-0432.CCR-23-3636 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Kunal B Desai Anthony V Serritella Walter M Stadler Peter H O'Donnell Randy F Sweis Russell Z Szmulewitz Source Type: research
An Unexpected Seminal Vesicle Pitfall in PSMA PET
Clin Nucl Med. 2024 Mar 25. doi: 10.1097/RLU.0000000000005183. Online ahead of print.ABSTRACTA 76-year-old man undergoing hormone therapy for prostate cancer was referred for 68Ga-PSMA-11-PET (PSMA PET) due to persistently detectable PSA level. No PSMA-positive tumor lesions were detected, so a delayed phase imaging was performed, which revealed focal PSMA uptake in the right seminal vesicle together with contrast accumulation on excretory phase contrast-enhanced CT. These findings were finally determined to be secondary to urinary reflux as a consequence of a prostatic enucleation he had undergone 5 months earlier followi...
Source: Clinical Prostate Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Angela Bronte Juan J Rosales Marcos Torres Roca Bernardino Mi ñana Macarena Rodr íguez-Fraile Source Type: research
Enchondroma on Bone Scan and PSMA PET/CT in a Patient With Prostate cancer
Clin Nucl Med. 2024 Mar 25. doi: 10.1097/RLU.0000000000005205. Online ahead of print.ABSTRACTA 54-year-old man with Gleason 9 prostate cancer with reported nodal and skeletal metastases was referred to us. Outside hospital reports described abnormal left proximal humerus activity on bone scan concerning for metastasis; however, concurrent PSMA PET/CT did not show activity in this lesion. Further review of the PET/CT images revealed characteristic features of enchondroma in the left humeral lesion.PMID:38537209 | DOI:10.1097/RLU.0000000000005205 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Charisma DeSai Lesley Flynt Sanjit Om Tewari Yang Lu Source Type: research
Complete Resolution of Locally Advanced Prostate Cancer After Molecular Endoradiotherapy With 177Lu-PSMA
Clin Nucl Med. 2024 Mar 25. doi: 10.1097/RLU.0000000000005163. Online ahead of print.ABSTRACTA 76-year-old man with castration-resistant prostate cancer underwent 68Ga-prostate-specific membrane antigen (PSMA) PET/CT for restaging. A large PSMA-avid tumor with invasion to adjacent organs was noted causing gross hematuria and symptomatic anemia. Two cycles of 177Lu-PSMA were administered, and the patient showed significant reduction of hematuria as well as declining in PSA levels. 177Lu-PSMA therapy can be a good treatment option in patients with locally invasive tumors.PMID:38537212 | DOI:10.1097/RLU.0000000000005163 (Sour...
Source: Clinical Prostate Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Mohsen Beheshti Reza Vali Soroush Zarehparvar Moghadam HamidReza Amini Masoumeh Hakiminejad GhasemAli Divband Source Type: research
Intense PSMA Uptake in Solitary Fibrous Tumor of the Seminal Vesicle
We describe 18F-PSMA-1007 PET/CT findings in a case of prostate adenocarcinoma with a solitary fibrous tumor of the left seminal vesicle. The solitary fibrous tumor showed intense 18F-PSMA-1007 uptake mimicking metastatic prostate adenocarcinoma. This case indicates that solitary fibrous tumor may cause false-positive result when using PSMA PET in staging of prostate cancer.PMID:38537218 | DOI:10.1097/RLU.0000000000005195 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Qian Zhao Aisheng Dong Huamao Ye Changjing Zuo Source Type: research
